administration reversed the impairment in the memory behavior (besides age of onset of impairment) may exist that have not been detected. Alternatively, the beretention in the water maze but not in the passive inhibition test and also markedly reduced intraneuronal havioral tests used to date may simply lack sensitivity to detect subtle, but real, differences in the cognitive Aβ42 in the hippocampus but not in the amygdala. Thus, there is a compelling association between intraphenotypes. In either case, truly rigorous side-by-side behavioral evaluation of these various models has not neuronal Aβ42 accumulation and behavioral alterations, but whether such data prove a cause and effect relabeen performed. If such testing were performed and showed similar phenotypes, then one could conclude tionship is likely to be debated. Indeed, these provocative studies probably raise more issues about intracellular Aβ than they answer.
In many mutant APP transgenic mice, intracellular Aβ42 accumulation has been detected, but relative to the impressive accumulation reported in the 3xTg-AD mice it is generally not a prominent pathologic feature (see Table 1 and Figure 1 ). In contrast, transgenic mice and rats expressing both mutant APP and PS typically exhibit more prominent intraneuronal Aβ42 immunoreactivity at a fairly early age. Yet, all of these models exhibit behavioral alterations that are at least superficially and qualitatively quite similar, and though the onset of the behavioral phenotype varies from model to model, so too does the onset of all forms of Aβ deposition and other pathologies (Ashe, 2001; Janus and Westaway, 2001). The apparent lack of truly distinct be- could be explained in a number of ways. Differences in either (1) that the intraneuronal Aβ42 accumulation is react to some degree with fragments of APP such as more of a marker associated with the presenilin transthose generated following β-secretase cleavage that gene and not causally linked to the behavioral alternacontain the Aβ42 sequence. Although biochemical and tion or that (2) that much lower levels of intraneuronal mass spectroscopic methods can be used to confirm Aβ42 can cause neuronal dysfunction in the APP-only the presence of Aβ42, using this technique to confirm mice. Alternatively, a quantitatively worse phenotype in the presence of intercellular Aβ42 in the brain is probthe mutant PS × mutant APP mice would support but lematic, as the extraction techniques invariably mix the not prove the assertion that intracellular Aβ42 contribextracellular and intracellular pools. Thus, to detect utes to or causes the observed behavioral alterations.
Aβ42 in situ it is important to use a panel of antibodies The rather remarkable observation that administrathat can detect other APP fragments. Lack of staining tion of anti-Aβ antibody reverses accumulation of Aβ42 with these antibodies can provide some assurance that within the hippocampal neurons and improves the defi-Aβ42 is in fact being detected. cit in spatial long-term memory assessed in the water Given the mechanistic questions raised, it may be maze is perhaps the most intriguing observation in the premature to conclude that intracellular Aβ42 causes current study. Although the authors use this data to the observed behavioral deficits in 3xTg-AD mice. support their conclusion that intraneuronal Aβ causes However, even if it is shown that intraneuronal Aβ42 is the behavioral deficits, without a precise mechanistic a consequence of extracellular stress induced perhaps understanding of how the antibody is working, other by small soluble aggregates of Aβ not detectable by possible explanations for this relationship need to be standard immunocytochemical methods, because of its considered. In this regard, it will be important to deterapparent toxicity intracellular Aβ42 could play a key mine the source of the intracellular Aβ and whether the downstream role mediating neuronal dysfunction (Laantibody is acting directly on intracellular Aβ42. AlFerla et al., 1995). Further study of the relationship bethough it is theoretically plausible to postulate that the tween behavioral impairments in any animal model of antibody is present within the neuron and binding Aβ in AD and Aβ accumulation, both inside and outside cells, manner that results in its clearance, there are no data is needed in order to determine which form or forms of to support such a mechanism. Thus, it is more plausible Aβ are linked to neuronal dysfunction in mice. Finally, to suggest that the antibody is binding extracellular the ultimate question for the field will be whether the Aβ42. If the source of intraneuronal Aβ is actually upfactors that cause cognitive changes in mouse models take of secreted Aβ42, then it is possible that the antiof AD also cause cognitive changes in humans. This body binding prevents its entry into the cell. However, if question will probably be answered only by developing intraneuronal Aβ42 is derived directly from intracellular selective therapies that target the causal factors in processing of APP, then it is more likely that the antibody is indirectly altering intraneuronal Aβ42. Indeed, it mice and then determining whether such therapies are may be that the intracellular Aβ42 observed in the effective in treating or preventing AD in humans. 3xTg-AD mice is simply a response to extracellular Aβ that can be "cleared" by the antibody.
In order to distinguish among these possible mechaTodd E. Golde and Christopher Janus nisms, several additional experiments need to be conDepartment of Neuroscience ducted. First, careful studies examining whether the Mayo Clinic anti-Aβ antibody gets into the neuron are needed. SeMayo Clinic College of Medicine cond, the precise subcellular localization of the intraJacksonville, Florida 32224 neuronal Aβ42 needs to be established. In this study, a diffuse cytoplasmic accumulation of Aβ42 is noted. This pattern of staining is quite distinct from the intraneuronal Aβ42 staining reported in humans with AD and 
